GSK PLC ADR (GSK): Price and Financial Metrics
GSK Price/Volume Stats
| Current price | $37.62 | 52-week high | $39.74 |
| Prev. close | $38.07 | 52-week low | $28.47 |
| Day low | $37.61 | Volume | 4,353,300 |
| Day high | $37.98 | Avg. volume | 3,355,511 |
| 50-day MA | $35.47 | Dividend yield | 3.78% |
| 200-day MA | $35.42 | Market Cap | 77.03B |
GSK Stock Price Chart Interactive Chart >
GSK POWR Grades
- Value is the dimension where GSK ranks best; there it ranks ahead of 97.45% of US stocks.
- GSK's strongest trending metric is Growth; it's been moving up over the last 177 days.
- GSK's current lowest rank is in the Momentum metric (where it is better than 9.57% of US stocks).
GSK Stock Summary
- GSK has a market capitalization of $70,052,400,000 -- more than approximately 96.83% of US stocks.
- With a price/earnings ratio of 3.83, GSK PLC P/E ratio is greater than that of about just 6.67% of stocks in our set with positive earnings.
- In terms of volatility of its share price, GSK is more volatile than just 2.86% of stocks we're observing.
- Stocks that are quantitatively similar to GSK, based on their financial statements, market capitalization, and price volatility, are STLA, GILD, CMI, NTES, and MCHP.
- Visit GSK's SEC page to see the company's official filings. To visit the company's web site, go to www.gsk.com.
GSK PLC ADR (GSK) Company Bio
GSK plc, formerly GlaxoSmithKline plc, is a British multinational pharmaceutical and biotechnology company with global headquarters in London, England. Established in 2000 by a merger of Glaxo Wellcome and SmithKline Beecham. GSK is the tenth largest pharmaceutical company and #294 on the 2022 Fortune Global 500, ranked behind other pharmaceutical companies China Resources, Sinopharm, Johnson & Johnson, Pfizer, Roche, AbbVie, Novartis, Bayer, and Merck. (Source:Wikipedia)
Latest GSK News From Around the Web
Below are the latest news stories about GSK PLC that investors may wish to consider to help them evaluate GSK as an investment opportunity.
FDA approves GSK's unique myelofibrosis treatment OjjaaraThe US Food and Drug Administration (FDA) has approved GlaxoSmithKline's (NYSE:GSK) novel treatment, Ojjaara (momelotinib), for adults with intermediate- or high-risk myelofibrosis and anemia. This announcement comes after a three-month delay due to the need for additional data review. |
FDA approves GSK's Ojjaara for treatment of myelofibrosis-related anaemiaThe FDA has approved Ojjaara, a drug developed by GSK plc (LSE:GSK), for the treatment of intermediate or high-risk myelofibrosis in adults with anaemia, the pharmaceutical company announced on Monday. The approval comes following a three-month delay due to an FDA request for additional information. |
Ojjaara (momelotinib) approved in the US as the first and only treatment indicated for myelofibrosis patients with anemiaLONDON, September 15, 2023--Ojjaara (momelotinib) approved in the US as the first and only treatment indicated for myelofibrosis patients with anemia |
CORRECTED-UPDATE 2-US FDA approves GSK's bone marrow cancer therapyBritish drugmaker GSK Plc said on Friday the U.S. Food and Drug Administration had approved its oral therapy to treat anemia in patients with a type of bone marrow cancer called myelofibrosis. The therapy, momelotinib, has been approved for patients "regardless of prior myelofibrosis therapy", according to GSK's statement on the FDA's approval. Myelofibrosis is associated with high levels of hepcidin and disrupts the body's production of blood cells, often causing severe anemia, or a deficiency of red blood cells. |
GSK launches £65m drug factory in HertfordshireGSK is opening a new £65m drug factory in Hertfordshire in a major boost for Britain’s life sciences sector. |
GSK Price Returns
| 1-mo | 7.64% |
| 3-mo | 4.46% |
| 6-mo | 11.63% |
| 1-year | 30.39% |
| 3-year | 14.06% |
| 5-year | 18.39% |
| YTD | 10.25% |
| 2022 | -16.73% |
| 2021 | 26.64% |
| 2020 | -17.79% |
| 2019 | 29.12% |
| 2018 | 13.70% |
GSK Dividends
| Ex-Dividend Date | Type | Payout Amount | Change | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Continue Researching GSK
Here are a few links from around the web to help you further your research on Glaxosmithkline Plc's stock as an investment opportunity:Glaxosmithkline Plc (GSK) Stock Price | Nasdaq
Glaxosmithkline Plc (GSK) Stock Quote, History and News - Yahoo Finance
Glaxosmithkline Plc (GSK) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...